194 related articles for article (PubMed ID: 30289161)
1. Long-term neurotoxicity and Raynaud's phenomenon in patients treated with cisplatin-based chemotherapy for malignant ovarian germ cell tumor.
Solheim O; Skalleberg J; Warncke T; Ørstavik K; Tropé C; Fosså SD
Acta Obstet Gynecol Scand; 2019 Feb; 98(2):240-249. PubMed ID: 30289161
[TBL] [Abstract][Full Text] [Related]
2. Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors.
Brydøy M; Oldenburg J; Klepp O; Bremnes RM; Wist EA; Wentzel-Larsen T; Hauge ER; Dahl O; Fosså SD
J Natl Cancer Inst; 2009 Dec; 101(24):1682-95. PubMed ID: 19940282
[TBL] [Abstract][Full Text] [Related]
3. Long-term ototoxicity in women after cisplatin treatment for ovarian germ cell cancer.
Skalleberg J; Solheim O; Fosså SD; Småstuen MC; Osnes T; Gundersen POM; Bunne M
Gynecol Oncol; 2017 Apr; 145(1):148-153. PubMed ID: 28202195
[TBL] [Abstract][Full Text] [Related]
4. Fertility and gonadal function after adjuvant therapy in women diagnosed with a malignant ovarian germ cell tumor (MOGCT) during the "cisplatin era".
Solheim O; Tropé CG; Rokkones E; Kærn J; Paulsen T; Salvesen HB; Hagen B; Vereide AB; Fosså SD
Gynecol Oncol; 2015 Feb; 136(2):224-9. PubMed ID: 25511159
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy-Induced Peripheral Neuropathy in Long-term Survivors of Childhood Cancer: Clinical, Neurophysiological, Functional, and Patient-Reported Outcomes.
Kandula T; Farrar MA; Cohn RJ; Mizrahi D; Carey K; Johnston K; Kiernan MC; Krishnan AV; Park SB
JAMA Neurol; 2018 Aug; 75(8):980-988. PubMed ID: 29799906
[TBL] [Abstract][Full Text] [Related]
6. Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy.
Fung C; Sesso HD; Williams AM; Kerns SL; Monahan P; Abu Zaid M; Feldman DR; Hamilton RJ; Vaughn DJ; Beard CJ; Kollmannsberger CK; Cook R; Althouse S; Ardeshir-Rouhani-Fard S; Lipshultz SE; Einhorn LH; Fossa SD; Travis LB;
J Clin Oncol; 2017 Apr; 35(11):1211-1222. PubMed ID: 28240972
[TBL] [Abstract][Full Text] [Related]
7. Malignant ovarian germ cell tumors: presentation, survival and second cancer in a population based Norwegian cohort (1953-2009).
Solheim O; Kærn J; Tropé CG; Rokkones E; Dahl AA; Nesland JM; Fosså SD
Gynecol Oncol; 2013 Nov; 131(2):330-5. PubMed ID: 24001518
[TBL] [Abstract][Full Text] [Related]
8. Peripheral neuropathy due to biweekly paclitaxel, epirubicin and cisplatin in patients with advanced ovarian cancer.
Postma TJ; Hoekman K; van Riel JM; Heimans JJ; Vermorken JB
J Neurooncol; 1999; 45(3):241-6. PubMed ID: 10845395
[TBL] [Abstract][Full Text] [Related]
9. Raynaud's phenomenon: a common toxicity after combination chemotherapy for testicular cancer.
Vogelzang NJ; Bosl GJ; Johnson K; Kennedy BJ
Ann Intern Med; 1981 Sep; 95(3):288-92. PubMed ID: 6168223
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin-associated neuropathy characteristics compared with those associated with other neurotoxic chemotherapy agents (Alliance A151724).
Albany C; Dockter T; Wolfe E; Le-Rademacher J; Wagner-Johnston N; Einhorn L; Lafky JM; Smith E; Pachman D; Staff N; Ma C; Loprinzi CL; Costello BA
Support Care Cancer; 2021 Feb; 29(2):833-840. PubMed ID: 32500206
[TBL] [Abstract][Full Text] [Related]
11. Retreatment with dose-dense weekly cisplatin after previous cisplatin chemotherapy is not complicated by significant neuro-toxicity.
van den Bent MJ; van Putten WL; Hilkens PH; de Wit R; van der Burg ME
Eur J Cancer; 2002 Feb; 38(3):387-91. PubMed ID: 11818204
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of pediatric and adolescent girls with malignant ovarian germ cell tumors.
Park JY; Kim DY; Suh DS; Kim JH; Kim YM; Kim YT; Nam JH
Gynecol Oncol; 2015 Jun; 137(3):418-22. PubMed ID: 25842162
[TBL] [Abstract][Full Text] [Related]
13. Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study.
Kerns SL; Fung C; Monahan PO; Ardeshir-Rouhani-Fard S; Abu Zaid MI; Williams AM; Stump TE; Sesso HD; Feldman DR; Hamilton RJ; Vaughn DJ; Beard C; Huddart RA; Kim J; Kollmannsberger C; Sahasrabudhe DM; Cook R; Fossa SD; Einhorn LH; Travis LB;
J Clin Oncol; 2018 May; 36(15):1505-1512. PubMed ID: 29617189
[TBL] [Abstract][Full Text] [Related]
14. Outcome of 3-day bleomycin, etoposide and cisplatin chemotherapeutic regimen for patients with malignant ovarian germ cell tumours: a Taiwanese Gynecologic Oncology Group study.
Chen CA; Lin H; Weng CS; Wen KC; Lu CH; Chou HH; Huang YF; Kang CY; Ho CM; Yu MH; Chou CY
Eur J Cancer; 2014 Dec; 50(18):3161-7. PubMed ID: 25459394
[TBL] [Abstract][Full Text] [Related]
15. Hypomagnesemia, renal dysfunction, and Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin.
Vogelzang NJ; Torkelson JL; Kennedy BJ
Cancer; 1985 Dec; 56(12):2765-70. PubMed ID: 2413982
[TBL] [Abstract][Full Text] [Related]
16. Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study--Pediatric Oncology Group 9049 and Children's Cancer Group 8882.
Cushing B; Giller R; Cullen JW; Marina NM; Lauer SJ; Olson TA; Rogers PC; Colombani P; Rescorla F; Billmire DF; Vinocur CD; Hawkins EP; Davis MM; Perlman EJ; London WB; Castleberry RP; ;
J Clin Oncol; 2004 Jul; 22(13):2691-700. PubMed ID: 15226336
[TBL] [Abstract][Full Text] [Related]
17. Feasibility and efficacy of gonadotropin-releasing hormone agonists for the prevention of chemotherapy-induced ovarian insufficiency in patients with malignant ovarian germ cell tumours (KGOG 3048R).
Choi MC; Chung YS; Lee JW; Kwon BS; Park BK; Kim SI; Shim SH; Lee KB; Seong SJ; Lee SJ; Lee SH; Yoo HJ; Song T; Kim MK; Baek MH; Kang S; Kim YM
Eur J Cancer; 2020 Jul; 133():56-65. PubMed ID: 32442924
[TBL] [Abstract][Full Text] [Related]
18. Associations between long-term serum platinum and neurotoxicity and ototoxicity, endocrine gonadal function, and cardiovascular disease in testicular cancer survivors.
Hjelle LV; Bremnes RM; Gundersen POM; Sprauten M; Brydøy M; Tandstad T; Wilsgaard T; Fosså SD; Oldenburg J; Haugnes HS
Urol Oncol; 2016 Nov; 34(11):487.e13-487.e20. PubMed ID: 27523611
[TBL] [Abstract][Full Text] [Related]
19. Psychometric evaluation of two scales assessing functional status and peripheral neuropathy associated with chemotherapy for ovarian cancer: a gynecologic oncology group study.
Almadrones L; McGuire DB; Walczak JR; Florio CM; Tian C
Oncol Nurs Forum; 2004 May; 31(3):615-23. PubMed ID: 15146227
[TBL] [Abstract][Full Text] [Related]
20. Long-term complications of chemotherapy for germ cell tumours.
Chaudhary UB; Haldas JR
Drugs; 2003; 63(15):1565-77. PubMed ID: 12887263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]